類器官及球狀體市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

2024 年全球類器官和球狀體市場價值為 15 億美元，預計到 2034 年將以 20.3% 的複合年成長率成長至 96 億美元。

隨著研究人員和開發人員越來越依賴比傳統2D系統更能模擬人體生理的先進3D細胞培養模型，市場擴張正在加速。這項轉變主要源自於再生醫學、腫瘤學和神經病學等領域對更精確、可擴展且符合倫理規範的臨床前解決方案的需求。患者來源的類器官和球狀體模型的日益普及也推動了產業發展，因為這些模型能夠提供關於個體治療反應和生物標記識別的寶貴資訊。這些平台透過讓科學家真實了解疾病特異性突變的行為方式以及患者細胞對藥物的反應，正在改變標靶治療的開發方式。它們的廣泛應用提高了預測的準確性，並減少了試誤法測試中常見的低效性。類器官和球狀體市場涵蓋廣泛的應用領域，包括藥物發現、毒性評估、再生醫學、疾病建模和個人化治療策略，從而推動了學術界、臨床和商業領域的強勁需求。

2024年，類器官市場佔了76.2%的佔有率。其主導地位源自於類器官能夠重現人體組織的功能和結構特徵，進而更可靠地模擬疾病機制和藥物反應。隨著研究人員擴大將類器官整合到個人化醫療流程中，尤其是在腫瘤學領域，患者特異性組織有助於更精準地選擇治療方案，因此對類器官的需求持續成長。類器官在再生醫學領域日益廣泛的應用也推動了其在肝臟、神經和腸道組織工程領域的應用。

由於藥物發現、毒性評估和個人化治療開發越來越依賴3D系統，預計到2024年，製藥和生物技術公司板塊將佔據42.3%的市場佔有率。這些公司正在整合基於類器官和球狀體的平台，以提高早期開發階段的預測準確性並減少臨床試驗失敗。各公司正在對高通量篩選系統進行大量投資，這些系統能夠利用3D培養同時測試多種化合物。

2024年，北美類器官和球狀體市場佔據42.7%的市場。強大的生物醫學研究能力、突破性技術的快速應用以及領先的製藥和生物技術開發商的積極參與，共同推動了該地區的成長。癌症、神經系統疾病和胃腸道疾病的日益普遍，促使人們更深入地應用與人體相關的臨床前模型。此外，由於充足的研究經費、不斷擴大的患者來源生物樣本庫以及類器官在精準醫療計畫中的廣泛應用，美國和加拿大基於類器官的研究活動也日益活躍。

類器官和球狀體市場的主要參與者包括ACROBiosystems、AMSBIO、ATCC、Corning、Lonza、DefiniGEN、Molecular Devices、Merck KGaA、Prellis Biologics和STEMCELL Technologies。這些公司正透過擴展其3D培養平台、加強與製藥和生物技術公司的合作以及投資自動化篩選技術來鞏固其競爭地位。許多公司正在開發針對特定疾病的類器官模型，以支持精準醫療計畫並打造差異化的產品組合。此外，各公司也正在改進其生產流程，以確保可擴展性、可重複性和合規性，這對於在藥物發現和臨床研究中更廣泛地應用至關重要。與學術機構和醫療保健提供者的策略合作有助於公司獲得多樣化的患者來源樣本，從而改善個人化治療工具。此外，成像、培養基和生物列印系統的技術升級也使該公司能夠提供更先進、更具商業可行性的3D細胞培養解決方案。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

• 產業生態系分析
  • 供應商格局
  • 每個階段的價值增加
  • 影響價值鏈的因素
• 產業影響因素
  • 成長促進因素
    • 細胞培養技術的進步
    • 對個人化醫療的需求不斷成長
    • 慢性病盛行率上升
    • 3D球體系統的技術進步
  • 產業陷阱與挑戰
    • 缺乏可靠的疾病模型
    • 開發和維護成本高昂
  • 市場機遇
    • 類器官生物樣本庫和罕見疾病建模的擴展
    • 人工智慧與數位平台的融合
• 成長潛力分析
• 監管環境
• 未來市場趨勢
• 技術格局
  • 目前技術
  • 新興技術
• 專利分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章：市場估算與預測：依類型分類，2021-2034年

• 主要趨勢
• 類器官
  • 按類型
    • 神經類器官
    • 肝臟類器官
    • 腸道類器官
    • 其他類器官類型
  • 透過方法
    • 類器官培養的通用浸沒法
    • 隱窩類器官培養技術
    • 氣液界面（ALI）法
    • 其他類器官培養方法
  • 按來源
    • 原代組織
    • 幹細胞
• 球狀體
  • 按類型
    • 多細胞腫瘤球體
    • 神經球
    • 乳腺球體
    • 肝球
  • 透過方法
    • 微圖案板
    • 低細胞黏附板
    • 懸滴法
    • 其他球狀體培養方法
  • 按來源
    • 細胞系
    • iPSCs衍生細胞

第6章：市場估算與預測：依應用領域分類，2021-2034年

• 主要趨勢
• 發育生物學
• 個人化醫療
• 再生醫學
• 疾病病理學研究
• 藥物毒性和療效測試

第7章：市場估算與預測：依最終用途分類，2021-2034年

• 主要趨勢
• 製藥和生物技術公司
• 學術和研究機構
• 醫院和診斷中心
• 其他最終用途

第8章：市場估算與預測：依地區分類，2021-2034年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• ACROBiosystems
• AMSBIO
• ATCC
• Corning
• DefiniGEN
• Lonza
• Merck KGaA
• Molecular Devices
• Prellis Biologics
• STEMCELL Technologies

The Global Organoids and Spheroids Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 20.3% to reach USD 9.6 billion by 2034.

Market expansion is accelerating as researchers and developers increasingly depend on advanced 3D cell culture models that mirror human physiology better than traditional 2D systems. This transition is largely fueled by the need for more accurate, scalable, and ethically acceptable preclinical solutions across areas such as regenerative medicine, oncology, and neurology. Growing adoption of patient-derived organoids and spheroids is also contributing to industry momentum, as these models deliver valuable insights into individual treatment responses and biomarker identification. These platforms are transforming targeted therapy development by giving scientists a realistic view of how disease-specific mutations behave and how patient cells react to drugs. Their growing use provides stronger predictability and decreases the inefficiencies often seen in trial-and-error testing. The organoids and spheroids market covers a broad spectrum of applications, including drug discovery, toxicity evaluation, regenerative medicine, disease modelling, and personalized therapeutic strategies, driving strong demand across academic, clinical, and commercial sectors.

The organoids segment held a 76.2% share in 2024. Its dominance stems from the ability of organoids to recreate functional and structural features of human tissues, resulting in more reliable modelling of disease mechanisms and drug responses. Demand continues to rise as researchers increasingly integrate organoids into personalized medicine workflows, particularly in oncology, where patient-specific tissue helps guide more precise therapy selection. Their expanding role in regenerative medicine is also spurring adoption across liver, neural, and intestinal tissue engineering initiatives.

The pharmaceutical and biotechnology companies segment held 42.3% share in 2024 due to growing reliance on 3D systems for drug discovery, toxicity evaluation, and personalized therapy development. These organizations are incorporating organoid- and spheroid-based platforms to enhance prediction accuracy during early development and reduce clinical trial failures. Companies are making sizable investments in high-throughput screening systems that allow simultaneous testing of multiple compounds using 3D cultures.

North America Organoids and Spheroids Market accounted for a 42.7% share in 2024. Regional growth is supported by strong biomedical research capabilities, rapid adoption of breakthrough technologies, and significant participation from leading pharmaceutical and biotech developers. The rising prevalence of cancer, neurological disorders, and gastrointestinal diseases is leading to deeper integration of human-relevant preclinical models. The U.S. and Canada are also witnessing increased activity in organoid-based research because of robust research funding, expanding patient-derived biobanks, and widespread use of organoids in precision medicine programs.

Key Organoids and Spheroids Market participants include ACROBiosystems, AMSBIO, ATCC, Corning, Lonza, DefiniGEN, Molecular Devices, Merck KGaA, Prellis Biologics, and STEMCELL Technologies. Companies in the Organoids and Spheroids Market are strengthening their competitive position by expanding their 3D culture platforms, increasing partnerships with pharmaceutical and biotech firms, and investing in automated screening technologies. Many are developing specialized, disease-focused organoid models to support precision medicine initiatives and create differentiated product portfolios. Firms are also enhancing their manufacturing processes to ensure scalability, reproducibility, and regulatory compliance, which is essential for broader adoption in drug discovery and clinical research. Strategic collaborations with academic institutes and healthcare providers help companies access diverse patient-derived samples, allowing them to refine personalized therapy tools. Additionally, technological upgrades in imaging, culture media, and bioprinting systems are enabling companies to deliver more advanced and commercially viable 3D cell culture solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Application trends
  • 2.2.4 End Use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancement in cell culture technologies
    • 3.2.1.2 Increase in demand for personalized medicine
    • 3.2.1.3 Rise in prevalence of chronic diseases
    • 3.2.1.4 Technological advancement in 3D spheroid systems
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of robust disease models
    • 3.2.2.2 High cost of development and maintenance
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of organoid biobanks and rare disease modeling
    • 3.2.3.2 Integration of AI and digital platforms
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Technological landscape
  • 3.6.1 Current technologies
  • 3.6.2 Emerging technologies
• 3.7 Patent analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Organoids
  • 5.2.1 By Type
    • 5.2.1.1 Neural organoids
    • 5.2.1.2 Hepatic organoids
    • 5.2.1.3 Intestinal organoids
    • 5.2.1.4 Other organoid types
  • 5.2.2 By Method
    • 5.2.2.1 General submerged method for organoid culture
    • 5.2.2.2 Crypt organoid culture techniques
    • 5.2.2.3 Air Liquid Interface (ALI) method
    • 5.2.2.4 Other organoid culture methods
  • 5.2.3 By Source
    • 5.2.3.1 Primary tissues
    • 5.2.3.2 Stem cells
• 5.3 Spheroids
  • 5.3.1 By Type
    • 5.3.1.1 Multicellular tumor spheroids
    • 5.3.1.2 Neurospheres
    • 5.3.1.3 Mammospheres
    • 5.3.1.4 Hepatospheres
  • 5.3.2 By Method
    • 5.3.2.1 Micropatterned plates
    • 5.3.2.2 Low cell attachment plates
    • 5.3.2.3 Hanging drop method
    • 5.3.2.4 Other spheroid culture methods
  • 5.3.3 By Source
    • 5.3.3.1 Cell line
    • 5.3.3.2 iPSCs derived cells

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Developmental biology
• 6.3 Personalized medicine
• 6.4 Regenerative medicine
• 6.5 Disease pathology studies
• 6.6 Drug toxicity & efficacy testing

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical & biotechnology companies
• 7.3 Academic & research institutes
• 7.4 Hospitals and diagnostic centers
• 7.5 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 ACROBiosystems
• 9.2 AMSBIO
• 9.3 ATCC
• 9.4 Corning
• 9.5 DefiniGEN
• 9.6 Lonza
• 9.7 Merck KGaA
• 9.8 Molecular Devices
• 9.9 Prellis Biologics
• 9.10 STEMCELL Technologies